ArticleJournal of molecular histology2026
Bellidifolin mitigates doxorubicin-induced myocardial injury via regulating oxidative stress, inflammation, and apoptosis: a combination of network pharmacology and experiments.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bellidifolin (BEL), the primary active compound in Gentianella acuta, demonstrates significant cardioprotective effects. This study aimed to investigate the protective role of BEL against DOX-induced myocardial injury and its mechanisms. Network pharmacology was utilized to identify possible therapeutic targets of BEL for disease treatment. In vivo, 30 C57BL/6 mice were randomly assigned to three experimental groups: Control, DOX, and BEL treatment (DOX + BEL). Mice were orally administered BEL (30 mg/kg) for 21 days, with a single intraperitoneal injection of DOX (15 mg/kg) on day 14. In vitro, H9c2 cells were used to assess the cardioprotective effects of BEL (50 µM) against DOX-induced toxicity. Cardiac function, myocardial histopathological changes, serum myocardial injury markers, oxidative stress indicators, and apoptosis were evaluated. Western blot analysis was conducted to detect the Nrf2/HO-1 and Galectin-3/NLRP3 pathway proteins. A total of 123 intersection targets were identified between BEL and disease-related proteins, including core targets such as caspase-3, IL-1β, and TNF. GO and KEGG pathway analyses revealed that BEL's protective effects against DOX-induced myocardial injury were associated with apoptosis, oxidative stress and inflammation. In vivo, BEL treatment improved cardiac function and myocardial histopathological morphology. BEL reduced MDA levels while increasing SOD and GSH-Px activity. Furthermore, BEL alleviated DOX-induced mitochondrial damage. BEL also decreased the apoptosis rate and modulated the expression of Caspase-3, Bax, and Bcl-2. Additionally, BEL activated the Nrf2/HO-1 pathway, as evidenced by increased nuclear translocation of Nrf2, upregulation of Nrf2, HO-1, GCLM, and NQO1 proteins, and a simultaneous decrease in Keap1 levels. BEL also suppressed the Galectin-3/NLRP3 inflammatory pathway, reducing the expression of Galectin-3, NLRP3, ASC, Caspase-1, IL-18, and IL-1β. In vitro, BEL treatment significantly decreased ROS levels induced by DOX. Overall, BEL mitigated DOX-induced cardiotoxicity by inhibiting oxidative stress, inflammation, and apoptosis via the Nrf2/HO-1 and Galectin-3/NLRP3 pathways.
Indexed as
Identifiers
41803446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.